Loading…
Hosted by The Lancet Oncology · 🇺🇰 uk · EN-UK · 222 episodes
Established thought leaders with verified media credentials.
The Lancet Oncology is a monthly journal, renowned for the publication of high-quality peer reviewed research, reviews and analysis in cancer from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue.
The Lancet Oncology hosts Listen to The Lancet Oncology, a science show with 222 episodes published.
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 ran
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discus
Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendati
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate
Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during r
Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.
Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.
Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate can
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlight
Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz and Dr Erica Kaye to discuss qualitative in oncology.
Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak and Dr Marissa Baker to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among
Dr Andre Pfob and Prof Peter Dubsky discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.
Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.
Deputy Editor Ali Landman speaks with Matthias Preusser about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-sm
Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, discusses his SunRISe4-trial published in our October issue.
Kat Gourd, Acting Deputy Editor of The Lancet Oncology , is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two excitin
Jinming Li discusses his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Listen to The Lancet Oncology has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Listen to The Lancet Oncology is hosted by The Lancet Oncology. The show is categorised under science (medicine) and has published 222 episodes.
Listen to The Lancet Oncology has published 222 episodes.
Listen to The Lancet Oncology regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Listen to The Lancet Oncology is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to The Lancet Oncology hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to The Lancet Oncology average 18 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to The Lancet Oncology's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 4 days ago.